Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Current Standards and New Directions in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Access Activity

Overview / Abstract:


Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening thrombotic microangiopathy with a rapid onset and progression and a mortality rate of 10% to 20% with prompt treatment. Onset of aTTP is characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, and a constellation of associated symptoms including hemorrhage, neurologic and renal manifestations, cardiac abnormalities, and mesenteric ischemia (Joly et al, 2017). Survivors of first aTTP events tend to have relapse events which need to be controlled. Rapid recognition and immediate appropriate treatment are critical for achieving optimized outcomes in aTTP. In this activity chaired by Spero Cataland, MD, Professor of Clinical Internal Medicine and Director of Benign Hematology at The Ohio State University, expert faculty will provide insightful guidance on current treatment standards and will discuss emerging therapies with the potential to improve patient outcomes in aTTP.


Hematology fellows, attending faculty, and other health care professionals involved in the treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP).


Upon completion of this activity, participants should be able to

-Evaluate the clinical and laboratory features of aTTP that can inform timely and accurate diagnosis
-Discuss how ADAMTS13 activity can be used to guide the management of aTTP
-Assess the mechanism of action, efficacy, and safety of novel anti-von Willebrand factor nanobodies in aTTP as elucidated by recent clinical trials
-Evaluate novel treatment combinations and sequences with the potential to improve the outcomes of patients with aTTP


May 15, 2025


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NCPD | 1.0 MOC | 1.0 ILNA



Presenters / Authors / Faculty

Spero R. Cataland, MD
Professor of Internal Medicine
Division of Hematology, Benign Hematology Section Head
Wexner Medical Center at The Ohio State University

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi.

Keywords / Search Terms

i3 Health Oncology, i3 Health, CME, NCPD, free CNE, free NCPD, Free CE, Free CME, Nursing, Oncology Nursing, Physician, Oncologist, nurse practitioner, physician assistants, oncology nurse, Medical oncologists, fellows, hematology Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map